Q4 FY2026 EarningsFY26 Q4 results beat consensus on the top line with revenue of $3,102M vs. $3,087M expected, driven by strong international CGM and consumables growth. However, GAAP EPS missed significantly at -$1.30 vs. -$0.14 expected due to $317M in one-time charges, including a $157M royalty obligation to Blackstone following MiniMed Flex FDA clearance and $118M in manufacturing restructuring costs. While international momentum remains robust (+21% YoY), U.S. sales grew only 2% as customers deferred purchases ahead of the new product launch.
Financial report interval: 2026.01.30 - 2026.04.30
Overview: MiniMed(MMED) the Revenue is 787 M (--%), Miss estimate;the EBIT is -59 M (--%), Beat estimate;the EPS is -0.68 (--%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.79B--
0.83B--
-0.04B--%
EBITExceed expectations
-0.06B--
-0.07B--
+0.01B--%
EPSMiss expectations
-0.68--
-0.3025--
-0.3775--%
Upcoming earnings report - FY2027 Q1 Earning Release
Available dateSep 1, 2026
Estimate Revenue828.43 M
Estimate EBIT32.48 M
Estimate EPS0.0985
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf